Mimi Lo

678 total citations
38 papers, 373 citations indexed

About

Mimi Lo is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Mimi Lo has authored 38 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Mimi Lo's work include CAR-T cell therapy research (11 papers), Multiple Myeloma Research and Treatments (10 papers) and Venous Thromboembolism Diagnosis and Management (6 papers). Mimi Lo is often cited by papers focused on CAR-T cell therapy research (11 papers), Multiple Myeloma Research and Treatments (10 papers) and Venous Thromboembolism Diagnosis and Management (6 papers). Mimi Lo collaborates with scholars based in United States and China. Mimi Lo's co-authors include Jeffrey A. Gilreath, Joseph Bubalo, Nina Shah, Chiung‐Yu Huang, Sandy W. Wong, Thomas Martin, Vanessa E. Kennedy, Swetha Kambhampati, Ying Sheng and R. Fong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mimi Lo

35 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mimi Lo United States 11 196 162 96 49 38 38 373
Knut Wendelin Germany 6 229 1.2× 374 2.3× 43 0.4× 40 0.8× 59 1.6× 12 629
Swetha Kambhampati United States 11 196 1.0× 83 0.5× 101 1.1× 72 1.5× 13 0.3× 29 424
Nicholas J. Gloude United States 8 98 0.5× 96 0.6× 39 0.4× 152 3.1× 24 0.6× 22 299
Julianna Roddy United States 11 108 0.6× 83 0.5× 37 0.4× 51 1.0× 14 0.4× 26 277
Robin Hume United States 8 77 0.4× 259 1.6× 44 0.5× 16 0.3× 21 0.6× 21 363
María Queralt Salas Spain 13 164 0.8× 338 2.1× 26 0.3× 110 2.2× 64 1.7× 57 476
Kazuo Hatanaka Japan 10 77 0.4× 157 1.0× 25 0.3× 51 1.0× 36 0.9× 33 264
Suheil Albert Atallah‐Yunes United States 8 172 0.9× 26 0.2× 42 0.4× 82 1.7× 34 0.9× 22 305
Dominic Kaddu‐Mulindwa Germany 8 100 0.5× 44 0.3× 41 0.4× 30 0.6× 58 1.5× 37 296
S. Qureshi United States 8 97 0.5× 162 1.0× 80 0.8× 16 0.3× 19 0.5× 22 303

Countries citing papers authored by Mimi Lo

Since Specialization
Citations

This map shows the geographic impact of Mimi Lo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mimi Lo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mimi Lo more than expected).

Fields of papers citing papers by Mimi Lo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mimi Lo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mimi Lo. The network helps show where Mimi Lo may publish in the future.

Co-authorship network of co-authors of Mimi Lo

This figure shows the co-authorship network connecting the top 25 collaborators of Mimi Lo. A scholar is included among the top collaborators of Mimi Lo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mimi Lo. Mimi Lo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ragavan, Meera Vimala, Scott J. Swartz, Mimi Lo, et al.. (2024). Access to Financial Assistance Programs and Their Impact on Overall Spending on Oral Anticancer Medications at an Integrated Specialty Pharmacy. JCO Oncology Practice. 20(2). 291–299. 5 indexed citations
2.
Reyes, Kevin, Chiung‐Yu Huang, Mimi Lo, et al.. (2023). Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplantation and Cellular Therapy. 29(6). 350–355. 26 indexed citations
3.
Lo, Mimi, et al.. (2023). Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplantation. 58(11). 1247–1253. 2 indexed citations
4.
Lo, Mimi, Rebecca Young, Ila M. Saunders, et al.. (2023). Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Journal of Oncology Pharmacy Practice. 29(7). 1715–1724. 1 indexed citations
5.
Khan, Fatima, et al.. (2023). Characterization of direct oral anticoagulants use in adult hematopoietic stem cell transplant recipients. Journal of Thrombosis and Thrombolysis. 57(2). 293–301.
6.
Huang, Chiung‐Yu, Mimi Lo, Shagun Arora, et al.. (2023). Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation and Cellular Therapy. 29(8). 504.e1–504.e7. 8 indexed citations
7.
Shah, Nina, Mimi Lo, Thomas G. Martin, et al.. (2023). Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma. Leukemia & lymphoma. 64(11). 1888–1891. 2 indexed citations
8.
Kambhampati, Swetha, Ying Sheng, Chiung‐Yu Huang, et al.. (2021). Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Advances. 6(7). 2045–2054. 79 indexed citations
9.
Banerjee, Rahul, Chiung‐Yu Huang, Mimi Lo, et al.. (2021). Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation and Cellular Therapy. 27(6). 477.e1–477.e7. 27 indexed citations
10.
Lo, Mimi, Rebecca Young, Chiung‐Yu Huang, et al.. (2021). Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. Transplantation and Cellular Therapy. 27(4). 344.e1–344.e5. 15 indexed citations
11.
Lee, Angela, et al.. (2021). Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thrombosis Research. 208. 148–155. 15 indexed citations
12.
Lo, Mimi, Thomas Martin, Jeffrey L. Wolf, et al.. (2021). Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma. Blood. 138(Supplement 1). 1759–1759. 3 indexed citations
13.
Gilreath, Jeffrey A., Mimi Lo, & Joseph Bubalo. (2021). Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs. 81(11). 1285–1305. 61 indexed citations
14.
Kambhampati, Swetha, Bita Fakhri, Ying Sheng, et al.. (2020). Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy. Blood. 136(Supplement 1). 4–5. 10 indexed citations
15.
Narayan, Rupa, Ann Lazar, R. Fong, et al.. (2020). Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. Clinical Lymphoma Myeloma & Leukemia. 20(12). e961–e985. 6 indexed citations
16.
17.
Banerjee, Rahul, Ann Lazar, Kelly Brassil, et al.. (2020). Digital Life Coaching for Myeloma Patients Undergoing Transplantation. Blood. 136(Supplement 1). 2–3. 3 indexed citations
18.
Kambhampati, Swetha, Bita Fakhri, Mimi Lo, et al.. (2019). Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series. Clinical Lymphoma Myeloma & Leukemia. 20(3). e118–e123. 16 indexed citations
19.
Kiel, Patrick J., et al.. (2008). An Evaluation of Amikacin Nephrotoxicity in the Hematology/Oncology Population. American Journal of Therapeutics. 15(2). 131–136. 7 indexed citations
20.
Pass, Kenneth A., et al.. (1996). Metabolic Screening via Heel Stick versus Umbilical Arterial Catheter— A Comparison. Clinical Pediatrics. 35(6). 333–334. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Knut Wendelin Breakdown of academic impact, for papers by Swetha Kambhampati Breakdown of academic impact, for papers by Nicholas J. Gloude Breakdown of academic impact, for papers by Julianna Roddy Breakdown of academic impact, for papers by Robin Hume Breakdown of academic impact, for papers by María Queralt Salas Breakdown of academic impact, for papers by Kazuo Hatanaka Breakdown of academic impact, for papers by Suheil Albert Atallah‐Yunes Breakdown of academic impact, for papers by Dominic Kaddu‐Mulindwa Breakdown of academic impact, for papers by S. Qureshi
Rankless by CCL
2026